Pharmacoeconomic evaluations of ceftriaxone and cefixime in the surgery department in a tertiary care teaching hospital
DOI:
https://doi.org/10.18203/2320-6012.ijrms20233707Keywords:
Pharmacoeconomic, Ceftriaxone, Cefixime, Cost Minimization AnalysisAbstract
Background: Pharmacoeconomics involves the analysis of the cost of drug therapy in the health systems which will play a significant role in drug product selection for formulary, comparison of alternative therapies pricing a product and evaluating a drug product and expected quality of life improvement. Objective were to assess pharmacoeconomic evaluation and cost minimization analysis of ceftriaxone and cefixime in the surgery department in a tertiary care teaching hospital.
Methods: This prospective observational study conducts to pharmacoeconomic evaluation of ceftriaxone and cefixime. It analyses the number of available brands and generic drugs and performs a cost-minimization analysis for these drugs used in the surgery department.
Results: The study includes a total of 173 patients, among them 68 patients (39%) were using ceftriaxone, 39 patients (23%) were using cefixime and 66 patients (38%) were using ceftriaxone and cefixime (IV-PO) for various surgery cases. Monocef (₹121.04; $1.04 per day) was the most commonly used ceftriaxone brand, while Gramocef (₹114; $1.38 per day) least and Xone (₹112; $1.38 per day) were the cheapest options. The mean ceftriaxone cost for a vial is 56.67±10.04 and the tablet is 113.33±20.08 per day. Cost minimization analysis shows that most prescribed drugs were costlier than least prescribed drugs. Taxim-O (₹107.72; $1.30 per strip) was the most prescribed cefixime brand and the least Tanfix ($ 1.3: ₹107 per strip). The mean of cefixime cost per strip is 107.6±0.28; $1.31 and per day 21.51±0.05; $ 0.26. There is no major cost difference or price variation in cefixime brands (0.69%).
Conclusions: The cheaper drugs should be prescribed to patients rather than the costlier and it should be the duty of healthcare professionals to consider the pharmacoeconomic value of drugs while prescribing the medications.
References
Rai M, Goyal R. Pharmacoeconomics in healthcare. In Pharmaceutical medicine and translational clinical research 2018;465-72.
Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of pharmacoeconomics in current Indian healthcare system. J Research Pharmacy Pract. 2013;2(1):3.
Shah JV, Patni KN, Deshpande SS. Pharmacoeconomic evaluation, cost minimization analysis of anti-diabetic therapy in Gujarat. Int J Med Res Heal Sci. 2016;5(3):34-43.
Bhosle D, Sayyed A, Bhagat A, Shaikh H, Sheikh A, Bhopale V et al. Comparison of generic and branded drugs on cost effective and cost benefit analysis. Ann Int Med Dental Res. 2016;3(1):35-7.
Kumari P, Siddegowda JB, Krishnaiah V. Appropriateness and pharmacoeconomics of surgical antimicrobial prophylaxis in open reduction internal fixation surgery practiced in a tertiary hospital compared to recommendations in the national center for disease control guidelines. Perspectives Clin Res. 2019;10(4):172.
Gorbach SL. The role of cephalosporins in surgical prophylaxis. J Antimicrobial Chemotherapy. 1989;23(D):61-70.
Davis R, Bryson HM. Ceftriaxone. Pharmacoeconomics. 1994;6(3):249-69.
Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics. 1994;5(2):20-6.
Gururaja MP. Cephalosporin utilization evaluation in a University Teaching Hospital: a prospective study. J Drug Delivery Therap. 2013 ;3(2).
Shankar PR, Partha P, Shenoy NK, Easow JM, Narayanan K, Prescribing patterns of antibiotics and sensitivity patterns of common microorganisms in the Internal Medicine ward of a teaching hospital in western Nepal: a prospective study, Ann Clin Microbiol Antimicrob. 2003;2(7):1-9.
Anderson G, Boldiston C, Woods S, O'Brien P. A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery. Arch Surg. 1996;131(7):744-8.
Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden A, Bolt D. Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: A prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery. World J Surg. 2005;29(1):18-24.
Mazza A. Ceftriaxone as short-term antibiotic prophylaxis in orthopaedic surgery: a cost-benefit analysis involving 808 patients. J Chemot. 2000;12(3):29-33.
Naimi HM, Rasekh H, Rahimi MH, Yousofi H. Assessment of the price-efficacy relationship for multiple brands of ceftriaxone sodium in Kabul: a cross- sectional study. BMC Res Notes. 2016;9(1):1-6.
Bhosle D, Sayyed A, Bhagat A, Shaikh H, Sheikh A, Bhopale V, Quazi Z. Comparison of generic and branded drugs on cost effective and cost benefit analysis. Ann. Int. Med. Dental Res. 2016;3(1):35-7.
Munckhof W, Antibiotics for surgical prophylaxis. Aust Prescr. 2005;28:38-40.
Periti P. Ceftriaxone for surgical prophylaxis: clinical experience &pharmacoeconomics. J Chemoth. 2000;12(3):2-4.
Gu S, Tang Z, Shi L, Sawhney M, Hu H, Dong H. Cost-minimization analysis of metformin and acarbose in treatment of type 2 diabetes. Value Heal Regional Issues. 2015;6:84-8
Omar S, Sharma S. Pharmacoeconomic Evaluation: Cost minimization analysis of different brands of calcium supplements in Kanpur. Pharma Innov J. 2018;7(7):221-7.
Meeradevi A, Deepa S. Cost minimization analysis of antimalarials in India. Int J Compr Adv Pharmacol. 2021;5(4):177-82.
Marupaka J, Akarapu S, Tamma NK, Karedla S. Cost analysis of drugs used for respiratory and gastrointestinal diseases A pharmacoeconomic study. National J Physiol Pharmacy Pharmacol. 2022;12(1):6.
Akku S, Garg A, Khandarkar S. Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia. Generics Biosimi Initiat J. 2016;5(4):164-8.
Malvankar-Mehta MS, Feng L, Hutnik CM. North American cost analysis of brand name versus generic drugs for the treatment of glaucoma. Clinicoeconomics Outcomes Res. 2019;11:789.
Purba AK, Setiawan D, Bathoorn E, Postma MJ, Dik JW, Friedrich AW. Prevention of surgical site infections: a systematic review of cost analyses in the use of prophylactic antibiotics. Frontiers Pharmacol. 2018;9:776.
Zhao Y, Feng HM, Qu J, Luo X, Ma WJ, Tian JH. A systematic review of pharmacoeconomic guidelines. J Med Economics. 2018;21(1):85-96.
Zhang WZ, Yu WJ, Zhao XL, He BX. Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain. Asian Pacific J Cancer Prevention. 2014;15(20):8797-800.
Kumari P, Siddegowda JB, Krishnaiah V. Appropriateness and pharmacoeconomics of surgical antimicrobial prophylaxis in open reduction internal fixation surgery practiced in a tertiary hospital compared to recommendations in the national center for disease control guidelines. Perspectives Clin Res. 2019;10(4):172.
Jn SK. Cost-effectiveness analysis in the management of stroke. Asian J Pharm Clin Res. 2017;10(7):127-30.
Gregory PS, David BM, James H, Jerome WA. Cost minimization analysis compairing azithromycin based and levofloksasin based protocols for the treatment of patients hospitalized with community acquired pneumonia. Chest. 2005;128:3246-54.
Vergnenegre A, Combescure C, Fournel P, Bayle S, Gimenez C, Souquet PJ et al. Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radio chemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01). Ann Ooncol. 2006;17(8):1269-74.